TickerFacts.

Emmaus Life Sciences, Inc. (EMMA): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.0K
Year ended 2025-12-31
$2.0K
Trailing 12 months to 2026-06-30
-66.2%
3-year compound annual growth
-41.8%
5-year compound annual growth
$127.9K2016-09-30: $4.0K2017-09-30: $127.9K2018-12-31: $94.0K2019-12-31: $60.0K2020-12-31: $15.0K2021-12-31: $73.0K2022-12-31: $26.0K2023-12-31: $17.0K2024-12-31: $12.0K2025-12-31: $1.0K$1.0K
2016-09-30 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$1.0K-91.7%2026-03-31, From 2025-01-01
2024-12-31$12.0K-29.4%2026-03-31, From 2024-01-01
2023-12-31$17.0K-34.6%2025-04-14, From 2023-01-01
2022-12-31$26.0K-64.4%2024-07-03, From 2022-01-01
2021-12-31$73.0K+386.7%2023-03-31, From 2021-01-01
2020-12-31$15.0K-75.0%2022-03-31, From 2020-01-01
2019-12-31$60.0K-36.2%2021-08-10, From 2019-01-01
2018-12-31$94.0Kn/a2021-01-25, From 2018-01-01
No annual figure between 2017-09-30 and 2018-12-31.
2017-09-30$127.9Kn/m2018-12-11, From 2016-10-01
2016-09-30$4.0Kn/a2017-12-29, From 2015-10-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$1.0K-91.7%
Prelude Therapeutics Inc (PRLD)2025-12-31$67.0K-91.2%
Evommune, Inc. (EVMN)2025-12-31$235.0K+167.0%
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$3.37Mn/m
Jaguar Health, Inc. (JAGX)2024-12-31$16.0Kn/a
CV Sciences, Inc. (CVSI)2025-12-31$109.0K+505.6%
Pyxis Oncology, Inc. (PYXS)2025-12-31$9.0K-96.2%
Arbutus Biopharma Corp (ABUS)2025-12-31$0-100.0%
Crescent Biopharma, Inc. (CBIO)2025-12-31$919.0Kn/m

Compare EMMA, PRLD, EVMN, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗